JP2019076039A - セレノネイン含有組成物 - Google Patents
セレノネイン含有組成物 Download PDFInfo
- Publication number
- JP2019076039A JP2019076039A JP2017206478A JP2017206478A JP2019076039A JP 2019076039 A JP2019076039 A JP 2019076039A JP 2017206478 A JP2017206478 A JP 2017206478A JP 2017206478 A JP2017206478 A JP 2017206478A JP 2019076039 A JP2019076039 A JP 2019076039A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- selenone
- aspergillus
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- MTIQLELFQVCRSW-ZETCQYMHSA-N selenoneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=[Se])N1 MTIQLELFQVCRSW-ZETCQYMHSA-N 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 claims abstract description 25
- 230000001737 promoting effect Effects 0.000 claims abstract description 24
- GYSDUVRPSWKYDJ-UHFFFAOYSA-N selinone Chemical compound C1=CC(OCC=C(C)C)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 GYSDUVRPSWKYDJ-UHFFFAOYSA-N 0.000 claims description 69
- 241000228212 Aspergillus Species 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 9
- 240000006439 Aspergillus oryzae Species 0.000 claims description 8
- 241000228245 Aspergillus niger Species 0.000 claims description 7
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 6
- 241000131386 Aspergillus sojae Species 0.000 claims description 6
- 241000134719 Aspergillus tamarii Species 0.000 claims description 6
- 241000122821 Aspergillus kawachii Species 0.000 claims description 5
- 241000228251 Aspergillus phoenicis Species 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 241001112078 Aspergillus usamii Species 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 2
- 230000001120 cytoprotective effect Effects 0.000 abstract description 32
- 230000036542 oxidative stress Effects 0.000 abstract description 22
- 239000004480 active ingredient Substances 0.000 abstract description 13
- 210000000056 organ Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 59
- 238000000034 method Methods 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 18
- 235000013305 food Nutrition 0.000 description 18
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 13
- 230000003833 cell viability Effects 0.000 description 13
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 13
- 229940093497 ergothioneine Drugs 0.000 description 13
- 239000011669 selenium Substances 0.000 description 13
- 229960001471 sodium selenite Drugs 0.000 description 13
- 239000011781 sodium selenite Substances 0.000 description 13
- 235000015921 sodium selenite Nutrition 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 12
- 229910052711 selenium Inorganic materials 0.000 description 12
- 229940091258 selenium supplement Drugs 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 229940065287 selenium compound Drugs 0.000 description 10
- 150000003343 selenium compounds Chemical class 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000054 fungal extract Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000013074 reference sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000459887 Aspergillus luchuensis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- -1 acidulants Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000018823 dietary intake Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- JULROCUWKLNBSN-UHFFFAOYSA-N selenocystine Chemical compound OC(=O)C(N)C[Se][Se]CC(N)C(O)=O JULROCUWKLNBSN-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229910052798 chalcogen Inorganic materials 0.000 description 1
- 150000001787 chalcogens Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 150000003966 selones Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
で表わされるセレノネインがある。
で示される、セレン化合物が知られている。
[1]セレノネインを含有する、細胞保護用組成物又は細胞増殖促進用組成物。
[2]前記組成物は、細胞培養のために用いられる組成物である、[1]に記載の組成物。
[3]前記セレノネインは、セレノネインを含有する形質転換体抽出物である、[1]〜[2]のいずれか1項に記載の組成物。
[4]前記形質転換体は、アスペルギルス属(Aspergillus)微生物の形質転換体である、[3]に記載の組成物。
[5]前記アスペルギルス属微生物は、アスペルギルス・ソーヤ(Aspergillus sojae)、アスペルギルス・オリゼ(Aspergillus oryzae)、アスペルギルス・ニガー(Aspergillus niger)、アスペルギルス・タマリ(Aspergillus tamarii)、アスペルギルス・リュチューエンシス(Aspergillus luchuensis)、アスペルギルス・ウサミ(Aspergillus usamii)、アスペルギルス・カワチ(Aspergillus kawachii)及びアスペルギルス・サイトイ(Aspergillus saitoi)からなる群から選ばれるアスペルギルス属微生物である、[4]に記載の組成物。
で表わされる化合物である。セレノネインは、式(I)の基本構造を有していれば、分子中のOH基、SeH基、NH基などが水素原子の無い状態、すなわち、イオン化した状態にあってもよい。
WO2017/026173号パンフレット(出願番号:PCT/JP2016/068128)に記載の遺伝子AsEgtAにより形質転換した形質転換アスペルギルス・ソーヤを用いて、同パンフレットに記載の例7に記載の方法により、セレノネイン含有糸状菌抽出物を得た。
(1)被験試料及び参考試料の調製
例1で得たセレノネイン含有糸状菌抽出物について、6倍希釈をするとセレノネイン(SeN)換算で1μM及び10μMになるように、培養培地を用いて被験試料1〜2を調製した。例えば、6倍希釈をするとセレノネイン換算で1μMになるようにするための被験試料1は、セレノネイン含有糸状菌抽出物をセレノネイン換算で6μM含む。
マウス由来の網膜神経節細胞株であるRGC−5細胞を、10vol% FBS、1vol% ペニシリン及び1vol% ストレプトマイシンを含むD−MEM培地(Low Glucose;Wako041−29775;以下、「培養培地」とよぶ。)を用いて0.5×104 cells/100μlになるように調製し、96ウェルプレートに播種した。細胞播種後の96ウェルプレートを、37℃、5%CO2の条件下で、オーバーナイトでインキュベートすることにより前培養を実施した。
Alamar Blue色素の酸化還元反応を利用して、細胞増殖や細胞毒性を定量する方法であるAlamar Blue Assayを実施するために、本培養後の96ウェルプレートの各ウェルに、alamarBlue(登録商標) Reagent(インビトロジェン社) 15μlを加え、37℃で2時間の反応に供した。反応後の96ウェルプレートの各ウェルについて、マクロプレートリーダー(「SpectraMax Gemini」;モレキュラー・デバイス社)を用いて、励起波長(Ex)を560nmとし、蛍光波長(Em)を590nmとして測定し、得られた測定結果からスタンダードの測定結果を基準として細胞生存率(Cell viability;%)を算出した。
被験試料1〜2、参考試料1−1〜1−2、参考試料2−1〜2−2、参考試料3−1〜3−2及びコントールの細胞生存率の結果をまとめたものを図1に示す。図中の記号について、コントロールを対照群として、ダネット(Dunnett)検定によりP<0.05で有意差があるものを「*」、P<0.01で有意差があるものを「**」、P<0.001で有意差があるものを「***」によって表わした。また、各試料の成分の含有量をまとめたものを表1に示す。
RGC−5細胞の代わりにヒト網膜色素上皮細胞株であるARPE19細胞を用いたことをのぞいては、例2と同様にして、被験試料1〜2及びセレノネインの最終濃度が100nM及び100μMになるように調製した被験試料3〜4;参考試料3−1〜3−2及び亜セレン酸ナトリウムの最終濃度が100nM及び100μMになるように調製した参考試料3−3〜3−4;並びにコントロールを用いて、セレノネインによる細胞保護効果を評価した。結果を図2A及び図2Bに示す。
Claims (5)
- セレノネインを含有する、細胞保護用組成物又は細胞増殖促進用組成物。
- 前記組成物は、細胞培養のために用いられる組成物である、請求項1に記載の組成物。
- 前記セレノネインは、セレノネインを含有する形質転換体抽出物である、請求項1〜2のいずれか1項に記載の組成物。
- 前記形質転換体は、アスペルギルス属(Aspergillus)微生物の形質転換体である、請求項3に記載の組成物。
- 前記アスペルギルス属微生物は、アスペルギルス・ソーヤ(A.sojae)、アスペルギルス・オリゼ(A.oryzae)、アスペルギルス・ニガー(A.niger)、アスペルギルス・タマリ(A.tamarii)、アスペルギルス・リュチューエンシス(A.luchuensis)、アスペルギルス・ウサミ(A.usamii)、アスペルギルス・カワチ(A.kawachii)及びアスペルギルス・サイトイ(A.saitoi)からなる群から選ばれるアスペルギルス属微生物である、請求項4に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017206478A JP7101363B2 (ja) | 2017-10-25 | 2017-10-25 | セレノネイン含有組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017206478A JP7101363B2 (ja) | 2017-10-25 | 2017-10-25 | セレノネイン含有組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019076039A true JP2019076039A (ja) | 2019-05-23 |
JP7101363B2 JP7101363B2 (ja) | 2022-07-15 |
Family
ID=66627098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017206478A Active JP7101363B2 (ja) | 2017-10-25 | 2017-10-25 | セレノネイン含有組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7101363B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021132655A1 (ja) | 2019-12-27 | 2021-07-01 | 国立研究開発法人国立成育医療研究センター | 受精卵のフラグメンテーション抑制剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011121914A (ja) * | 2009-12-11 | 2011-06-23 | Fisheries Research Agency | 新規セレン含有化合物 |
WO2017026173A1 (ja) * | 2015-08-07 | 2017-02-16 | キッコーマン株式会社 | セレノネインの製造方法 |
-
2017
- 2017-10-25 JP JP2017206478A patent/JP7101363B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011121914A (ja) * | 2009-12-11 | 2011-06-23 | Fisheries Research Agency | 新規セレン含有化合物 |
WO2017026173A1 (ja) * | 2015-08-07 | 2017-02-16 | キッコーマン株式会社 | セレノネインの製造方法 |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 24, JPN6021031264, 2010, pages 18134 - 18138, ISSN: 0004695029 * |
WORLD JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Vol.1, Issue.5, JPN6021031263, 2010, pages 144 - 150, ISSN: 0004695028 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021132655A1 (ja) | 2019-12-27 | 2021-07-01 | 国立研究開発法人国立成育医療研究センター | 受精卵のフラグメンテーション抑制剤 |
Also Published As
Publication number | Publication date |
---|---|
JP7101363B2 (ja) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019230183A1 (ja) | 乳酸菌及びその用途 | |
AU2006318357B2 (en) | Algal and algal extract dietary supplement composition | |
JP5517215B2 (ja) | 発酵及び培養方法、植物発酵エキス、植物発酵エキス末並びに該植物発酵エキス配合物 | |
JP2008156330A (ja) | 賦活化剤及び抗老化剤 | |
JPWO2017135466A1 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
RU2370155C1 (ru) | Биологически активная добавка к пище, обладающая антитоксическими свойствами | |
JP2017031121A (ja) | Ampk活性化剤 | |
JP7101363B2 (ja) | セレノネイン含有組成物 | |
JP6148780B1 (ja) | キサントフィルとヒシ属植物の加工物を含有する組成物 | |
CN105558887B (zh) | 富硒蛋黄粉及其生产方法 | |
JP3829107B2 (ja) | 免疫反応性NO合成を誘導するiNOS酵素を刺激する組成剤およびその製造方法 | |
JP2008239549A (ja) | 細胞外マトリックス産生向上剤 | |
KR102158134B1 (ko) | 오미자 추출물을 유효성분으로 함유하는 항균용 조성물 | |
KR102501955B1 (ko) | 동과 발효 추출물을 유효성분으로 함유하는 면역 증진용 조성물 | |
KR102244732B1 (ko) | 프로바이오틱 초산균인 아세토박터 파스테리아누스 mglv 및 이의 면역조절 효과 | |
Kazemi et al. | Evaluation the effect of royal jelly on the growth of two members of gut microbiota; Bacteroides fragillis and Bacteroides thetaiotaomicron. | |
JP5578160B2 (ja) | 植物由来の賦活化剤及び細胞外マトリックス産生促進剤 | |
WO2015002279A1 (ja) | グルタチオン生成促進用組成物 | |
JP4873605B2 (ja) | 穀類由来の成分を有効成分とする血管新生阻害の作用を有する組成物 | |
Askarov et al. | Chemical composition of the rose hip and preparation of useful food compounds | |
KR20200078109A (ko) | 세넨데스무스 인터메디우스 가공 추출물을 유효성분으로 하는 항균 및 항산화 조성물 | |
JP2020063216A (ja) | 経口組成物 | |
KR102470357B1 (ko) | 락토코커스 락티스 q1 균주를 포함하는 면역증진용 조성물 | |
RU2716058C1 (ru) | Функциональный пищевой продукт из черноморской мидии mytilus galloprovincialis lam. | |
KR102606636B1 (ko) | 근감소증 예방 또는 개선 효과를 갖는 바실러스 벨레젠시스 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201002 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220301 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220621 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220624 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7101363 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |